Search - tctmd.com

Displaying 21 - 40 of 57

Sort: Relevancy | Date

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

Time and Money: PCI Public Reporting Requirements Takes Their Toll

News Conference News ACC 2019

Time and Money: PCI Public Reporting Requirements Take Their Toll

Michael O'Riordan

March 26, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

Presentation ACC 2018

One-year Clinical Outcomes of the Bio-engineered COMBO stent: Primary Results from the 3614 All-comer Patients in the COMBO Collaboration

Presenter: Antonio Colombo

March 11, 2018

News Conference News ACC 2018

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Yael L. Maxwell

March 11, 2018

Presentation ACC 2018

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Presenter: Ajay J. Kirtane

March 11, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

Presentation ACC 2016

Outcomes of the ABSORB Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The ABSORB III randomized trial

Presenter: Gregg W. Stone

April 03, 2016

News Conference News ACC 2015

Outcomes at 5 Years Reinforce Durability of Stenting for Unprotected Left Main Disease

L.A. McKeown

March 15, 2015

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

Presentation ACC 2014

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presenter: Masahiro Natsuaki

March 31, 2014

Presentation ACC 2014

The Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS)

Presenter: M. Valgimigli

March 31, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

Presentation ACC 2013

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Presenter: Ian T. Meredith

March 09, 2013

Advertisement

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Time and Money: PCI Public Reporting Requirements Take Their Toll

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

One-year Clinical Outcomes of the Bio-engineered COMBO stent: Primary Results from the 3614 All-comer Patients in the COMBO Collaboration

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Outcomes of the ABSORB Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The ABSORB III randomized trial

Outcomes at 5 Years Reinforce Durability of Stenting for Unprotected Left Main Disease

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

The Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS)

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content